Society for Neuro-Oncology Annual Meeting (SNO) | Conference

Patients with newly diagnosed glioblastoma saw improved progression-free survival when treated with tumor treating fields, pembrolizumab, and temozolomide versus historical control data.

Epigenetic lesions, and not just genetic mutations, can cause brain cancer, and one important implication of that observation is that precision-medicine genetic and genomic tools will miss epigenetic lesions that may drive tumor growth or drug resistance.

IDH1-mutant gliomas can affect adjacent, nonmalignant cells in ways that trigger seizures, according to research reported at the 21st Annual Scientific Meeting of the Society for Neuro-Oncology.

Computer analysis of subvisual data extracted from routine clinical MRI exams outperforms human experts at differentiating brain tumor recurrence from radiation necrosis.

In this interview we discuss findings from M12-356, an open-label, phase I, escalation cohort study of the investigational anti-EGFR antibody-drug conjugate ABT-414 for patients with EGFR-amplified recurrent glioblastoma.

Four years in the making, the new 2016 World Health Organization Classification of Tumors of the Central Nervous System includes new genetically identified entities and variants, allowing more diagnostic precision, and a new “layered” approach to diagnosis.

Caring for patients with brain tumors can have marked effects on the well-being of oncology clinicians, frequently leading to burnout, and authors of an ongoing survey study aim to get a clearer picture of those impacts.

The anti-inflammatory ibudilast shows early preclinical promise against glioblastoma cell lines when combined with temozolomide, according to new research.

In this interview we discuss updates, challenges, and contributing factors associated with pediatric brain cancers.

In this interview we discuss fatigue, cognitive dysfunction, and psychiatric problems in patients with glioma and review which patients are more likely to encounter these issues.